Neonatal Alloimmune Thrombocytopenia
Neonatal alloimmune thrombocytopenia is a serious blood disorder that occurs when a mother’s immune system attacks her baby’s platelets during pregnancy or shortly after birth. Although many cases are mild, this condition is the most common cause of severe low platelet counts in newborns and can lead to dangerous bleeding, including life-threatening brain hemorrhage.
Table of contents
- What is Neonatal Alloimmune Thrombocytopenia?
- How Common is This Condition?
- What Causes NAIT?
- Signs and Symptoms
- Serious Complications
- How is NAIT Diagnosed?
- Treatment During Pregnancy
- Treatment After Birth
- Subsequent Pregnancies
NAIT, FNAIT, fetal and neonatal alloimmune thrombocytopenia, fetomaternal alloimmune thrombocytopenia, FMAIT
What is Neonatal Alloimmune Thrombocytopenia?
Neonatal alloimmune thrombocytopenia is a blood disorder that affects babies either before they are born or shortly after delivery. The condition occurs when the mother’s immune system produces antibodies that attack and destroy her baby’s platelets (blood cells that help stop bleeding).[1]
This happens because the baby’s platelets carry certain markers, called antigens, that are inherited from the father but are not present on the mother’s own platelets. When the mother’s immune system encounters these unfamiliar antigens, it treats them as foreign invaders and creates antibodies against them. These antibodies then cross the placenta and attack the baby’s platelets, causing thrombocytopenia (a low platelet count).[4]
The condition is similar to Rh disease (also known as hemolytic disease of the newborn), but instead of affecting red blood cells, NAIT affects platelets. An important difference is that NAIT can affect the first pregnancy, unlike Rh disease which typically affects subsequent pregnancies.[6]
How Common is This Condition?
The exact frequency of neonatal alloimmune thrombocytopenia varies depending on the study. Research suggests that NAIT occurs in approximately one out of every 800 to 1,000 live births.[1] Some studies report rates between one in 350 and one in 5,000 live births.[6]
However, many experts believe the condition is underdiagnosed because mild cases may go unnoticed or be mistaken for other conditions. Some researchers estimate the true prevalence may be closer to one in 600 to 1,200 live births.[5]
There is currently no national screening program for NAIT in any country, which means many cases are only discovered when symptoms appear in the newborn or after a history of affected siblings.[6]
What Causes NAIT?
NAIT is caused by the transfer of maternal antibodies across the placenta. These antibodies are directed against human platelet antigens (HPAs) that the baby inherited from the father but that are absent on the mother’s platelets.[6]
To date, 24 different human platelet-specific antigens have been identified. In white populations, the most common trigger is an antigen called HPA-1a, which accounts for 75 to 80 percent of NAIT cases. The second most common is HPA-5b, responsible for 10 to 15 percent of cases.[6]
Between 1.6 and 4.6 percent of the general population test negative for the HPA-1a antigen, meaning they could potentially develop antibodies if they become pregnant with a baby who has this antigen.[6]
The mother is usually exposed to the baby’s blood during pregnancy or delivery. This exposure triggers her immune system to produce antibodies. Unlike some other pregnancy-related conditions, NAIT can occur during the first pregnancy.[6]
Signs and Symptoms
The symptoms of neonatal alloimmune thrombocytopenia vary widely depending on how low the platelet count drops. Many cases are mild and may not cause noticeable symptoms at all. Frequently, the affected baby remains largely without symptoms and no treatment is needed.[5]
When symptoms do appear, the most common visible signs include petechiae (tiny red or purple spots on the skin caused by bleeding under the skin) and ecchymosis (bruising). These bleeding spots may be mistakenly dismissed as birth trauma or a newborn rash.[7]
It is important to understand that visible external signs are not always an indication of how severe the platelet destruction actually is. Some babies may have very low platelet counts without obvious external symptoms.[7]
In more severe cases, babies may exhibit bleeding complications at birth or within a few hours after delivery. This can include bleeding into major organs such as the stomach, spinal cord, kidneys, or liver.[7]
Other symptoms can include localized swelling called a hematoma, excessive bleeding after routine procedures like vitamin K injections or circumcision, and in severe cases, neurological signs such as abnormal heart rate patterns.[4]
Serious Complications
The most serious complication of neonatal alloimmune thrombocytopenia is intracranial hemorrhage (bleeding into the brain). This is the most feared outcome because it can lead to death or cause permanent neurological damage.[1]
NAIT is the most common cause of intracranial hemorrhage in full-term infants. Studies show that approximately 10 percent of symptomatic babies die from brain bleeding, and about 20 percent of affected infants develop long-term neurological problems.[5]
Most concerning is that 80 percent of intracranial hemorrhages occur before birth, meaning the damage happens while the baby is still in the womb.[5] After delivery, the greatest risk of bleeding is within the first four days of life.[5]
Long-term disabilities caused by brain hemorrhage can include hydrocephalus (fluid buildup in the brain), blindness affecting the visual processing areas of the brain, epilepsy (seizure disorder), cerebral palsy (movement and posture disorders), early puberty, and various sensory, motor, and cognitive developmental delays.[7]
Recent research has also suggested possible links between NAIT and miscarriage, restricted fetal growth, and damage to the retina (the light-sensitive tissue at the back of the eye).[7]
How is NAIT Diagnosed?
The diagnosis of neonatal alloimmune thrombocytopenia is usually made after an unexpected finding of a low platelet count on a blood test, or because of bleeding complications in the newborn.[5]
Universal screening programs do not currently include testing for NAIT. As a result, the first case in a family is usually unexpected and diagnosed only after symptoms appear in the baby.[4] The best indicator of risk for a current pregnancy is a history of an affected sibling.[6]
When NAIT is suspected, diagnostic testing involves examining both parents and the baby. This includes determining the platelet antigen types (phenotyping) of both the mother and father, and screening the mother’s blood serum for anti-platelet antibodies. More detailed genetic testing (genotyping) can be performed to determine the exact nature of the incompatibility.[4]
Laboratory testing typically shows neonatal platelet counts under 20,000 platelets per microliter (normal ranges are 150,000 to 450,000). Higher counts may suggest a different diagnosis, such as maternal immune thrombocytopenic purpura.[4]
After birth, babies suspected of having NAIT are screened for intracranial hemorrhage using imaging techniques, and their platelet counts are carefully monitored.[4]
Treatment During Pregnancy
When neonatal alloimmune thrombocytopenia is diagnosed or suspected during pregnancy (usually because of a previously affected child), several treatment approaches may be considered to protect the developing baby.
The main treatment approach involves administering intravenous immunoglobulin (IVIG) to the pregnant mother. IVIG is a blood product containing antibodies that can help reduce or prevent the effects of NAIT in the baby. Treatment typically involves weekly infusions throughout the pregnancy until delivery.[4]
In some cases, doctors may also prescribe corticosteroids (such as prednisone) in combination with IVIG, although the use of steroids remains somewhat controversial.[6]
Pregnant women being treated for NAIT should avoid medications that can further reduce platelet counts, including non-steroidal anti-inflammatory drugs like ibuprofen and aspirin.[4]
Some medical centers may perform invasive procedures to check the baby’s platelet count before birth, but this carries risks and is not routinely recommended. Management strategies and the timing of delivery are carefully planned based on the severity of the condition and whether there was a previously affected sibling.[6]
Treatment After Birth
After delivery, newborns with confirmed or suspected neonatal alloimmune thrombocytopenia require immediate evaluation and monitoring. The baby’s platelet count is checked, and imaging studies may be performed to rule out intracranial hemorrhage.[4]
Treatment depends on the severity of the thrombocytopenia and whether there are signs of bleeding. Options include:
- Platelet transfusions: Babies with very low platelet counts or active bleeding may receive transfusions of compatible platelets. Ideally, these should be platelets that lack the antigen that triggered the mother’s antibodies. Maternal platelets can be used after being washed and treated, as they naturally lack the problematic antigen.[9]
- Intravenous immunoglobulin (IVIG): Newborns may receive IVIG treatment, which can help increase platelet counts by reducing platelet destruction.[4]
- Monitoring: Even babies without symptoms require careful monitoring because platelet counts may remain low for several weeks after birth as maternal antibodies gradually clear from the baby’s system.[1]
Most affected babies recover completely within 2 to 8 weeks as the maternal antibodies are eliminated from their circulation.[1]
Subsequent Pregnancies
One of the most important aspects of neonatal alloimmune thrombocytopenia is that there is a very high risk of recurrence in subsequent pregnancies. Often, the condition becomes more severe with each affected pregnancy.[6]
Women who have had one baby with NAIT should inform their healthcare providers before planning another pregnancy. This allows for proper counseling, monitoring, and early treatment to reduce the risk of serious complications in future babies.[9]
With appropriate management during pregnancy, including IVIG therapy and careful planning of delivery, the success rate for protecting subsequent babies is extremely high.[7]
Couples may also benefit from genetic counseling to understand the inheritance patterns and risks for future pregnancies. The father’s genetic testing can help determine the likelihood that future children will inherit the problematic platelet antigen.[4]
